BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pfizer Inc. (PFE) Asks End to Fen-Phen Suits Linked to Lung Ailment


8/23/2012 7:35:33 AM

Pfizer Inc. (PFE), whose Wyeth unit set aside more than $21 billion to settle lawsuits over the fen-phen diet drug, is asking a judge to throw out claims that the pills caused a fatal disease years after users stopped taking them. Pfizer’s lawyers will ask a federal judge in Philadelphia today to bar cases from going to trial that allege former fen- phen users developed primary pulmonary hypertension, also known as PPH, nine or more years after they last used the appetite suppressant. Wyeth withdrew the diet combination from the market in 1997 after it was linked to heart problems and PPH, an often- fatal lung ailment.

Read at BusinessWeek

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES